Is there scope for widening patient engagement in drug development? Does it matter how and why we do it? onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
Exploring Vocabularies of Motive to Optimise Patient Engagement for Drug Development
Patient engagement in the drug development life cycle is becoming normalised, and the return on investment is being quantified. We sought to understand what motivates biotechnology organisations to u...